Compugen's Q2 Revenues Rise on Collaboration Fees

The firm swung to a loss from a profit a year ago, but that was due to a gain on the sale of Evogene shares during last year's Q2.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories